Table 2. International Guidelines on Adjuvant Systemic Treatment of Elderly Breast Cancer Patients.

Consensus panel (update year)	Recommendations
SIOG/EUSOMA (2010)	Decision to treat with chemotherapy should not be based on age alone AC and CMF are preferred to monotherapy capecitabine Anthracycline-containing regimen is preferred to CMF Taxane can be added to anthracycline in high-risk healthy elderly patients or substituted for anthracycline to decrease cardiac risk HER2-positive tumours should be treated with trastuzumab+chemotherapy in patients without cardiac disease
St Gallen (2015)	No age cutoff Treatment should be based on disease characteristics, co-morbidity, life expectancy and patient preference
ASCO (2015)	Consider life expectancy, risks and benefits of the treatment, and patient preference Systemic therapy should be offered to patients with life expectancy >5 years HER2-positive small node-negative tumours: consider paclitaxel and trastuzumab HER2-positive larger tumours: consider TCH that has more favourable toxicity profile compared with anthracycline, taxane and trastuzumab combination

Abbreviations: AC=doxorubicin and cyclophosphamide; CMF=cyclophosphamide, methotrexate and fluorouracil; SIOG=International Society of Geriatric Oncology; EUSOMA=European Society of Breast Cancer Specialists; St Gallen=St Gallen International Expert Consensus; ASCO=American Society of Clinical Oncology; TCH=docetaxel, carboplatin and trastuzumab.